From $0 to $15 billion in less than two years. That's what Pfizer (NYSE:PFE) expects to achieve at a minimum with Comirnaty (BNT162b2), the COVID-19 vaccine it markets with BioNTech (NASDAQ:BNTX). 

However, there are good reasons to look for the actual sales total for Pfizer's COVID-19 vaccine to be a lot higher than $15 billion. Last week, results from two studies were announced that bode well for Comirnaty. Pfizer could be an even bigger winner than anticipated after these two fantastic findings.